openPR Logo
Press release

Global Biosimilars Treatment Market 2022: Amgen Inc., Biocon, Roche Ltd., Celltrion, Inc.

10-04-2017 02:27 PM CET | Health & Medicine

Press release from: QYResearchReports

Global Biosimilars Treatment Market 2022: Amgen Inc., Biocon,

This report studies the global Biosimilars Treatment market, analyzes and researches the Biosimilars Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy's Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Get Report Sample and Customization: https://www.qyresearchreports.com/sample/sample.php?rep_id=1336465&type=E

List of Tables and Figures

Figure Biosimilars Treatment Product Scope
Figure Global Biosimilars Treatment Market Size (Million USD) (2012-2017)
Table Global Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Biosimilars Treatment Market Share by Regions in 2016
Figure United States Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure EU Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Japan Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure China Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure India Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Southeast Asia Biosimilars Treatment Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Biosimilars Treatment Market Share by Type in 2016

QYResearchReports.com is an unimpeachable source of market research data for clients that comprise acclaimed SMEs, Chinese companies, private equity firms, and MNCs. We provide market research reports on various categories such as Energy, Chemicals, Alternative and Green Energy, Manufacturing, Machinery, Pharmaceuticals and Materials, and Glass.

Contact us

Brooklyn, NY 11230
United States
Toll Free: 866-997-4948 (USA-CANADA)
Tel: +1-518-621-2074
Web: http://www.qyresearchreports.com
Email: sales@qyresearchreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilars Treatment Market 2022: Amgen Inc., Biocon, Roche Ltd., Celltrion, Inc. here

News-ID: 755474 • Views: 430

More Releases from QYResearchReports

Global Oilfield Communication Equipment Market Latest Achievements and Opportuni …
Qyresearchreports include new market research report Global Oilfield Communication Equipment Market Insights, Forecast to 2025 to its huge collection of research reports. The Oilfield Communication Equipment market was valued at Million US$ in 2018 and is projected to reach Million US$ by 2025, at a CAGR of during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to
Global Power Over Ethernet (POE) Lighting Market : Key Growth Factors and Foreca …
Qyresearchreports include new market research report Global Power Over Ethernet (POE) Lighting Market Insights, Forecast to 2025 to its huge collection of research reports. This report presents the worldwide Power Over Ethernet (POE) Lighting market size (value, production and consumption), splits the breakdown (data status 2013-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities
Global Automatic Palletizer and Depalletizer Market to be at Forefront by 2025 | …
Qyresearchreports include new market research report Global Automatic Palletizer and Depalletizer Market Insights, Forecast to 2025 to its huge collection of research reports. Automatic palletizer and depalletizer is a machine that enables automatic stacking of goods and products. It also enables the depalletizing or unloading of goods. The rising consumer income and European Central Bank (ECB) bond-buying program will influence the buying pattern of consumers in EMEA and will result in
Global Weather Forecasting Equipment Market Advancement Analysis and Precise Out …
Qyresearchreports include new market research report Global Weather Forecasting Equipment Market Insights, Forecast to 2025 to its huge collection of research reports. The Weather Forecasting Equipment market was valued at Million US$ in 2018 and is projected to reach Million US$ by 2025, at a CAGR of during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to

All 5 Releases


More Releases for Biosimilars

PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on